Antimalarial drug prescribing practice in private and public health facilities in South-east Nigeria: a descriptive study by Meremikwu, Martin et al.
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
Malaria Journal
Open Access Research
Antimalarial drug prescribing practice in private and public health 
facilities in South-east Nigeria: a descriptive study
Martin Meremikwu*1, Uduak Okomo1, Chukwuemeka Nwachukwu1, 
Angela Oyo-Ita1, John Eke-Njoku1, Joseph Okebe1, Esu Oyo-Ita2 and 
Paul Garner3
Address: 1Institute of Tropical Diseases Research and Prevention, University of Calabar Teaching Hospital, Calabar, GPO Box 1211, Nigeria, 
2Department of Medical Services, Cross River State Ministry of Health Headquarters, Calabar and 3Liverpool School of Tropical Medicine, UK
Email: Martin Meremikwu* - mmeremiku@yahoo.co.uk; Uduak Okomo - uokomo@mrc.gm; 
Chukwuemeka Nwachukwu - dremeka31@yahoo.com; Angela Oyo-Ita - oyo_ita@yahoo.com; John Eke-Njoku - john_azubuike@yahoo.com; 
Joseph Okebe - j_okebs@yahoo.com; Esu Oyo-Ita - nehcap@yahoo.co.uk; Paul Garner - pgarner@liverpool.ac.uk
* Corresponding author    
Abstract
Background:  Nigeria's national standard has recently moved to artemisinin combination
treatments for malaria. As clinicians in the private sector are responsible for attending a large
proportion of the population ill with malaria, this study compared prescribing in the private and
public sector in one State in Nigeria prior to promoting ACTs.w:\fmbatch_out
Objective: To assess prescribing for uncomplicated malaria in government and private health
facilities in Cross River State.
Method: Audit of 665 patient records at six private and seven government health facilities in 2003.
Results: Clinicians in the private sector were less likely to record history or physical examination
than those in public facilities, but otherwise practice and prescribing were similar. Overall, 45% of
patients had a diagnostic blood slides; 77% were prescribed monotherapy, either chloroquine
(30.2%), sulphadoxine-pyrimethamine (22.7%) or artemisinin derivatives alone (15.8%). Some
20.8% were prescribed combination therapy; the commonest was chloroquine with sulphadoxine-
pyrimethamine. A few patients (3.5%) were prescribed sulphadoxine-pyrimethamine-mefloquine in
the private sector, and only 3.0% patients were prescribed artemisinin combination treatments.
Conclusion: Malaria treatments were varied, but there were not large differences between the
public and private sector. Very few are following current WHO guidelines. Monotherapy with
artemisinin derivatives is relatively common.
Background
The Nigerian government has recently changed its policy
guidelines for treating uncomplicated malaria to arte-
mether-lumefantrine or amodiaquine plus artesunate
replacing monotherapy with chloroquine and sulfadox-
ine-pyrimethamine (SP). The policy change became nec-
essary because the therapeutic efficacy of chloroquine and
SP had deteriorated [1]. Any introduction of new treat-
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ments will require evidence from audit to understand cur-
rent prescribing practices, and training to provide
guidance [2]. The success of a new treatment policy would
depend on the adherence of health providers and patients
to the recommendations [3], and, in Nigeria, as in many
other countries, there is a powerful pharmaceutical indus-
try that aims to influence prescribing in both the private
and public sector. Clinicians in the private sector are often
thought to use more irrational treatments than in the pub-
lic sector. In Nigeria, the private sector is responsible for
treating over half of malaria cases [4]. To help understand
the current prescribing practice, an audit of prescribing
practices for malaria was conducted in both government
and private facilities in Cross River State, South-eastern
Nigeria.
Methods
The study was conducted in a sample of 13 health facili-
ties situated in rural and urban areas of Cross River State
Nigeria between August and December 2003. The study
area is located within the tropical rain forest belt of South-
eastern Nigeria, and has an annual rainfall of 2000–3000
millimeters. Malaria transmission is intense and peren-
nial in this area. A recent study in the area showed the
therapeutic efficacy of chloroquine and sulphadoxine-
pyrimethamine to be below 25% [1]. In the government
sector, data were collected from the six functioning hospi-
tals. In the private sector, permission was sought from the
seven clinics and all consented. Of the total of 13 facilities,
eight were urban and five rural.
In each facility, the individual records of patients recently
treated for uncomplicated malaria as diagnosed by the cli-
nician within six months of the study were audited. If no
diagnosis was recorded, uncomplicated malaria was
defined as fever with malaria parasitaemia in patients that
were not severely unwell. A total of 30–90 records were
assessed per facility depending on the out-patient attend-
ance of each facility. Two paediatrics registrars and two
medical officers were trained on the study procedure, and
worked concurrently in a single team to extract data from
patient record files in the selected health facilities using
pre-tested data extraction forms.
Data obtained included patients age, sex, symptoms,
signs, diagnostic tests and antimalarial drugs used.
"Detailed history recorded" was classified when the
attending clinician had in addition to a list and duration
of the main symptoms, documented associated symp-
toms, past medical history, family and social history.
There were insufficient data in the patients' records to
determine the appropriateness of the treatment dosages
using the drug dosage tables derived from recommenda-
tions of the national malaria treatment guideline and the
World Health Organization as planned. The State Ministry
of Health approved the study. The confidentiality of the
patients' record and clinicians' identity were adequately
protected. Data entry and analysis were with EPI-INFO
2002.
Results
Of the 665 patient records assessed across the 13 health
facilities, about half were from government services
(Table 1); about half were adults. Government services
were more likely to record the history or physical exami-
nation (Table 2). Malaria blood slides were only per-
formed in 45% of patients, with no difference between
private and public sector. Almost all who were screened
for parasites were positive, probably because positive par-
asitaemia was a criterion for case definition of malaria in
this study. Most cases were with a low parasitaemia.
Monotherapy was 77% of all prescriptions. The common-
est drug prescribed was chloroquine (30.2%), followed by
sulphadoxine-pyrimethamine (22.7%) and artemisinin
alone (15.8%). There was little difference between private
and government services. Combination therapy was
20.8% of all prescriptions, and commonest combination
treatment was chloroquine with sulphadoxine-pyrimeth-
amine. Only 20 patients in total received artemisinin
combined with other drugs (3.0%), mostly artemether-
lumefantrine in the government sector. Mefloquine-sul-
phadoxine-pyrimethamine was used in the private sector
and formed 20.8% (11/53) of their combination treat-
ments. There was insufficient information to determine
whether 15 (2.2%) of the prescriptions were combination
treatments or not.
Discussion
This study has shown a wide variety of anti-malaria drug
prescribing, but with overall prescribing in government
and private facilities being remarkably similar. Mono-
therapy with chloroquine, sulphadoxine-pyrimethamine
and artemisinin compounds were the first, second and
third most common prescription practices respectively. As
this audit was conducted in a period when Nigeria was
transiting from chloroquine to artemisinin-based combi-
nation therapy (ACT) as recommended treatment for
uncomplicated malaria, it is not surprising perhaps that
this audit reflects old recommendations. What is, how-
ever, of concern was the high use of artemisinin mono-
therapy which was neither a recommendation in the old
nor the new national treatment policy [5]. The current
WHO treatment guideline for uncomplicated malaria dis-
courages artemisinin monotherapy [6]. Irrational use of
artemisinin and its derivatives as monotherapy could
negate one of the goals of combination therapy which is
to prevent the emergence of drug resistant malaria para-
sites [7,8].Malaria Journal 2007, 6:55 http://www.malariajournal.com/content/6/1/55
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Table 2: Prescription pattern for antimalarial drug combination and monotherapy
Antimalarial drug regimens prescribed Frequency of prescription (% n)
Government hospitals (n = 348) Private Clinics (n = 317)
Monotherapy 263(75.6) 264 (83.3)
Chloroquine 82 (23.6) 119 (37.5)
Sulphadoxine-pyrimethamine (SP) 92 (26.4) 59 (18.6)
Artemisinin 59 (16.9) 46 (14.5)
Quinine 16 (4.6) 28 (8.8)
Halofantrine 2 (0.6) 6 (1.9)
Amodiaquine 3 (0.9) 0 (0.0)
Combination therapy 85 (24.4) 53 (16.7)
Chloroquine-SP 35 (10.1) 16 (5.0)
Quinine-SP 32 (9.2) 24 (7.6)
Mefloquine-SP 0 (0.0) 11 (3.5)
Artemisinin-SP 2 (0.6) 2 (0.6)
Artemether+lumefantrine 16 (4.6) 0 (0.0)
Insufficient data to determine 9 (2.6) 6 (1.9)
Table 1: Patient characteristics and physician's assessment
Characteristics Patients (%)
Government hospitals Private clinics Total
Numbers studied 348 (52.3) 317 (47.7) 665 (100)
Residence Rural 160 (46.0) 79 (24.9) 239 (35.9)
Urban 186 (53.4) 238 (75.1) 424 (63.8)
Not specified 2 (0.6) 0 (0.0) 2 (0.3)
Age (years) <5 84 (24.1) 44 (13.9) 128 (19.3)
5+ 223 (64.1) 135 (42.6) 358 (53.8)
Not specified by clinician 41 (11.8) 138 (43.5) 179 (26.9)
Gender Female 192 (55.2) 144 (45.4) 336 (50.5)
Male 156 (44.8) 161 (50.8) 317 (47.7)
Not specified 0 (0.0) 12 (3.8) 12 (1.8)
Clinical Assessment Malaria blood smear 
performed
45.9% (157) 44.1% (137) 44.2% (294)
Detailed history recorded 25.1% (86) 4.8% (15) 15.2% (101)
General exam or one 
system
73.1% (250) 38.6% (120) 55.6% (370)
Malaria parasite blood slide 
results*
Number assessed (n)** 156 139 295
Scanty 35 (22.4) 13 (9.3) 48 (16.3)
+ 82 (52.6) 80 (57.6) 162 (54.9)
++ 31 (19.9) 41 (29.5) 72 (24.4)
+++/numerous 5 (3.2) 4 (2.9) 9 (3.0)
Negative 3 (1.9) 1 (0.7) 4 (1.4)
* Species not specified; usually P. falciparum > 95% in the area.
** Percentage of number assessed (n)Malaria Journal 2007, 6:55 http://www.malariajournal.com/content/6/1/55
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A Nigerian survey of malaria control practices showed that
less than a fifth of the primary and secondary health facil-
ities studied used the recommended malaria treatment
guidelines [4]. Lack of adherence to malaria treatment
guidelines was associated with inappropriate prescribing
practices in rural Kenya [9]. Poor drug use practices like
use of sub-therapeutic doses or failing to complete pre-
scribed doses are among factors that could lead to emer-
gence and spread of mutant resistant strains of Plasmodium
falciparum [7]. Poor adherence to prescriptions tends to
occur more with drug regimens that have long treatment
durations such as artemisinin monotherapy that takes
seven days than artemisinin combination treatments that
take only three days [10]. The practice of artemisinin
monotherapy in this part of Nigeria if unchecked, could
compromise the efficacy of artemisinin compounds.
Clarity of guidelines, strong evidence, adequate funding
of guidelines and support by opinion leaders especially
professional bodies are some of the factors that positively
influence the use of clinical guidelines [11]. There is a
need for in-depth study of factors that affect the dissemi-
nation and use of treatment guidelines in Nigeria.
The private sector is a leading provider of malaria case
management in many endemic countries [12], and
responsible for treating over 50% of malaria cases in
Nigeria [4]. While this study showed no significant differ-
ence in prescribing practice between private and govern-
ment health care service, it showed deficiencies in both
sectors, and poor adherence to national and WHO guide-
lines. As Nigeria introduces a new treatment regimen,
efforts to improve malaria treatment practices should
therefore target both private and government-supported
health providers. Training programmes in malaria case
management should include private sector providers.
Also private-public partnership in the procurement, distri-
bution and use of good quality anti-malaria drugs should
also be encouraged to minimize the circulation of sub-
standard drugs. Recent report of studies in some Southeast
Asian countries revealed that a significant proportion of
the artemisinin drugs used in those countries were sub-
standard [13]. It is important to establish effective surveil-
lance mechanisms to prevent the same unscrupulous
suppliers from contaminating the Nigerian anti-malarial
drug supply chain.
Medical record systems in the health facilities involved in
this study were suboptimal with incomplete documenta-
tion of treatment details which made it difficult to assess
the appropriateness of antimalarial drug dosage. Availa-
bility of modern medical record system has been identi-
fied as a key factor facilitating clinical audit [14].
Modernizing medical record systems in Nigeria will facil-
itate the development of clinical auditing. There is need to
develop and effectively disseminate evidence-based prac-
tice guidelines as a strategy for improving prescribing
practice in both public and private health care facilities.
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